Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

  • Michele Kohli1Email author,
  • Donna Lawrence1,
  • Jennifer Haig1,
  • Andrea Anonychuk2 and
  • Nadia Demarteau2
BMC Public Health201212:872

DOI: 10.1186/1471-2458-12-872

Received: 24 February 2012

Accepted: 8 October 2012

Published: 13 October 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
24 Feb 2012 Submitted Original manuscript
16 Mar 2012 Reviewed Reviewer Report - Mark Jit
23 Mar 2012 Reviewed Reviewer Report - Iacopo Baussano
30 Jul 2012 Author responded Author comments - Michele Kohli
Resubmission - Version 2
30 Jul 2012 Submitted Manuscript version 2
14 Aug 2012 Reviewed Reviewer Report - Mark Jit
22 Aug 2012 Reviewed Reviewer Report - Iacopo Baussano
2 Oct 2012 Author responded Author comments - Michele Kohli
Resubmission - Version 3
2 Oct 2012 Submitted Manuscript version 3
Publishing
8 Oct 2012 Editorially accepted
13 Oct 2012 Article published 10.1186/1471-2458-12-872

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
OptumInsight, Health Economics and Outcomes Research
(2)
GlaxoSmithKline Biologicals, Global Vaccines Development

Advertisement